CAR T Cell Therapy Breyanzi^® (lisocabtagene maraleucel) Approved for Second-Line Relapsed or Refractory Diffuse Large B-cell Lymphoma

Bristol Myers Squibb Canada announced Health Canada’s approval of Breyanzi®, a type of CAR T therapy, for the treatment of adult patients with diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and high-grade B-cell lymphoma.